Gilead Sciences acquisition of MYR: A strategic move to tackle hepatitis delta virus

In a strategic acquisition aimed at expanding its hepatitis treatment portfolio, US biopharmaceutical giant Gilead Sciences has announced the acquisition of MYR GmbH, a German ... Read More